Cargando…

Utilizing a Dynamical Description of IspH to Aid in the Development of Novel Antimicrobial Drugs

The nonmevalonate pathway is responsible for isoprenoid production in microbes, including H. pylori, M. tuberculosis and P. falciparum, but is nonexistent in humans, thus providing a desirable route for antibacterial and antimalarial drug discovery. We coordinate a structural study of IspH, a [4Fe-4...

Descripción completa

Detalles Bibliográficos
Autores principales: Blachly, Patrick G., de Oliveira, César A. F., Williams, Sarah L., McCammon, J. Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868525/
https://www.ncbi.nlm.nih.gov/pubmed/24367248
http://dx.doi.org/10.1371/journal.pcbi.1003395
_version_ 1782296462554562560
author Blachly, Patrick G.
de Oliveira, César A. F.
Williams, Sarah L.
McCammon, J. Andrew
author_facet Blachly, Patrick G.
de Oliveira, César A. F.
Williams, Sarah L.
McCammon, J. Andrew
author_sort Blachly, Patrick G.
collection PubMed
description The nonmevalonate pathway is responsible for isoprenoid production in microbes, including H. pylori, M. tuberculosis and P. falciparum, but is nonexistent in humans, thus providing a desirable route for antibacterial and antimalarial drug discovery. We coordinate a structural study of IspH, a [4Fe-4S] protein responsible for converting HMBPP to IPP and DMAPP in the ultimate step in the nonmevalonate pathway. By performing accelerated molecular dynamics simulations on both substrate-free and HMBPP-bound [Fe(4)S(4)](2+) IspH, we elucidate how substrate binding alters the dynamics of the protein. Using principal component analysis, we note that while substrate-free IspH samples various open and closed conformations, the closed conformation observed experimentally for HMBPP-bound IspH is inaccessible in the absence of HMBPP. In contrast, simulations with HMBPP bound are restricted from accessing the open states sampled by the substrate-free simulations. Further investigation of the substrate-free simulations reveals large fluctuations in the HMBPP binding pocket, as well as allosteric pocket openings – both of which are achieved through the hinge motions of the individual domains in IspH. Coupling these findings with solvent mapping and various structural analyses reveals alternative druggable sites that may be exploited in future drug design efforts.
format Online
Article
Text
id pubmed-3868525
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38685252013-12-23 Utilizing a Dynamical Description of IspH to Aid in the Development of Novel Antimicrobial Drugs Blachly, Patrick G. de Oliveira, César A. F. Williams, Sarah L. McCammon, J. Andrew PLoS Comput Biol Research Article The nonmevalonate pathway is responsible for isoprenoid production in microbes, including H. pylori, M. tuberculosis and P. falciparum, but is nonexistent in humans, thus providing a desirable route for antibacterial and antimalarial drug discovery. We coordinate a structural study of IspH, a [4Fe-4S] protein responsible for converting HMBPP to IPP and DMAPP in the ultimate step in the nonmevalonate pathway. By performing accelerated molecular dynamics simulations on both substrate-free and HMBPP-bound [Fe(4)S(4)](2+) IspH, we elucidate how substrate binding alters the dynamics of the protein. Using principal component analysis, we note that while substrate-free IspH samples various open and closed conformations, the closed conformation observed experimentally for HMBPP-bound IspH is inaccessible in the absence of HMBPP. In contrast, simulations with HMBPP bound are restricted from accessing the open states sampled by the substrate-free simulations. Further investigation of the substrate-free simulations reveals large fluctuations in the HMBPP binding pocket, as well as allosteric pocket openings – both of which are achieved through the hinge motions of the individual domains in IspH. Coupling these findings with solvent mapping and various structural analyses reveals alternative druggable sites that may be exploited in future drug design efforts. Public Library of Science 2013-12-19 /pmc/articles/PMC3868525/ /pubmed/24367248 http://dx.doi.org/10.1371/journal.pcbi.1003395 Text en © 2013 Blachly et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Blachly, Patrick G.
de Oliveira, César A. F.
Williams, Sarah L.
McCammon, J. Andrew
Utilizing a Dynamical Description of IspH to Aid in the Development of Novel Antimicrobial Drugs
title Utilizing a Dynamical Description of IspH to Aid in the Development of Novel Antimicrobial Drugs
title_full Utilizing a Dynamical Description of IspH to Aid in the Development of Novel Antimicrobial Drugs
title_fullStr Utilizing a Dynamical Description of IspH to Aid in the Development of Novel Antimicrobial Drugs
title_full_unstemmed Utilizing a Dynamical Description of IspH to Aid in the Development of Novel Antimicrobial Drugs
title_short Utilizing a Dynamical Description of IspH to Aid in the Development of Novel Antimicrobial Drugs
title_sort utilizing a dynamical description of isph to aid in the development of novel antimicrobial drugs
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868525/
https://www.ncbi.nlm.nih.gov/pubmed/24367248
http://dx.doi.org/10.1371/journal.pcbi.1003395
work_keys_str_mv AT blachlypatrickg utilizingadynamicaldescriptionofisphtoaidinthedevelopmentofnovelantimicrobialdrugs
AT deoliveiracesaraf utilizingadynamicaldescriptionofisphtoaidinthedevelopmentofnovelantimicrobialdrugs
AT williamssarahl utilizingadynamicaldescriptionofisphtoaidinthedevelopmentofnovelantimicrobialdrugs
AT mccammonjandrew utilizingadynamicaldescriptionofisphtoaidinthedevelopmentofnovelantimicrobialdrugs